Results 11 to 20 of about 8,521 (239)

Characterization of GPVI- or GPVI-CD39-Coated Nanoparticles and Their Impact on In Vitro Thrombus Formation [PDF]

International Journal of Molecular Sciences, 2021
Traditional antithrombotic agents commonly share a therapy-limiting side effect, as they increase the overall systemic bleeding risk. A novel approach for targeted antithrombotic therapy is nanoparticles. In other therapeutic fields, nanoparticles have enabled site-specific delivery with low levels of toxicity and side effects.
Jeremy Nestele, Anne‐Katrin Rohlfing, Valerie Dicenta, Alexander Bild, Daniela Eißler, Fréderic Emschermann, Marcel Kremser, Konstantin Krutzke, Tilman E. Schäffer, Oliver Borst, Moran Levi, Netanel Korin, Meinrad Gawaz   +12 more
openalex   +5 more sources

Relative antithrombotic effect of soluble GPVI dimer compared with anti-GPVI antibodies in mice [PDF]

Blood, 2004
AbstractGlycoprotein VI (GPVI) is an essential platelet collagen receptor; therefore, the inhibition of GPVI-collagen interactions may be an attractive antithrombotic strategy. We have previously shown that targeting of GPVI with antibodies leads to the depletion of the receptor and to long-term antithrombotic protection in mice.
Sabine Grüner, Miroslava Prostredná, Martina Koch, Yoshiki Miura, Valerie Schulte, Stéphanie Jung, Masaaki Moroi, Bernhard Nieswandt   +7 more
openalex   +3 more sources

Immobilized collagen prevents shedding and induces sustained GPVI clustering and signaling in platelets [PDF]

Platelets, 2021
Collagen, the most thrombogenic constituent of blood vessel walls, activates platelets through glycoprotein VI (GPVI). In suspension, following platelet activation by collagen, GPVI is cleaved by A Disintegrin And Metalloproteinase (ADAM)10 and ADAM17 ...
Chiara Pallini, Jeremy A. Pike, Christopher O’Shea, Robert K. Andrews, Elizabeth E. Gardiner, Steve P. Watson, Natalie S. Poulter   +6 more
doaj   +4 more sources

Liver-mediated shedding of platelet GPVI [PDF]

Blood, 2016
The in vivo mechanisms underlying antibody-based shedding of the key platelet collagen receptor glycoprotein VI (GPVI) are potentially significant for future antibody-based thromboprotective agents.
Michael C. Berndt, Robert K. Andrews
openalex   +5 more sources

Comparison of the GPVI inhibitors losartan and honokiol [PDF]

Platelets, 2020
Losartan and honokiol are small molecules which have been described to inhibit aggregation of platelets by collagen. Losartan has been proposed to block clustering of GPVI but not to affect binding of collagen. Honokiol has been reported to bind directly
Marie-Blanche Onselaer, Magdolna Nagy, Chiara Pallini, Jeremy A Pike, Gina Perrella, Lourdes Garcia Quintanilla, Johannes A Eble, Natalie S. Poulter, Johan W.M. Heemskerk, Steve P Watson   +9 more
doaj   +4 more sources

Non-genomic effects of PPARgamma ligands: inhibition of GPVI-stimulated platelet activation [PDF]

, 2010
BACKGROUND: Peroxisome proliferator-activated receptor-(gamma) (PPAR(gamma)) is expressed in human platelets although in the absence of genomic regulation in these cells, its functions are unclear.
Akbiyik, Ali, Ali, Asselin, Beckman, Chapelsky, Chinetti, Cicmil, Cicmil, Croxtall, Dayuan, Dormandy, Falati, Gibbins, Gibbins, Gibbins, Gross, Hsueh, Hubbard, Irons, Jones, Jones, Khanolkar, Lago, Lehmann, Lipscombe, Losel, Malaver, McGuire, Moraes, Moraes, Moraes, Moro, Nieswandt, Nieuwenhuis, Nissen, O’Brien, Patil, Poole, Randriamboavonjy, Sauer, Smith, Tucker, Weyrich   +43 more
core   +4 more sources

Structure-function relationship of the platelet glycoprotein VI (GPVI) receptor: does it matter if it is a dimer or monomer? [PDF]

Platelets, 2021
GPVI is a critical signaling receptor responsible for collagen-induced platelet activation and a promising anti-thrombotic target in conditions such as coronary artery thrombosis, ischemic stroke, and atherothrombosis. This is due to the ability to block
Joanne C. Clark, Foteini-Nafsika Damaskinaki, Yam Fung Hilaire Cheung, Alexandre Slater, Steve P. Watson   +4 more
doaj   +2 more sources

Fibrin and D-dimer bind to monomeric GPVI [PDF]

Blood Advances, 2017
: Fibrin has recently been shown to activate platelets through the immunoglobulin receptor glycoprotein VI (GPVI). In the present study, we show that spreading of human platelets on fibrin is abolished in patients deficient in GPVI, confirming that ...
Marie-Blanche Onselaer, Alexander T. Hardy, Clare Wilson, Ximena Sanchez, Amir K. Babar, Jeanette L.C. Miller, Callum N. Watson, Stephanie K. Watson, Arkadiusz Bonna, Helen Philippou, Andrew B. Herr, Diego Mezzano, Robert A.S. Ariëns, Steve P. Watson   +13 more
doaj   +6 more sources

GPVI expression is linked to platelet size, age, and reactivity [PDF]

Blood Advances, 2022
Abstract Platelets within one individual display heterogeneity in reactivity, size, age, and expression of surface receptors. To investigate the combined intraindividual contribution of platelet size, platelet age, and receptor expression levels on the reactivity of platelets, we studied fractions of large and small platelets from ...
Alicia Veninga, Stefan Handtke, Konstanze Aurich, Bibian M. E. Tullemans, Sanne L. N. Brouns, S Schwarz, Floor Heubel-Moenen, Andreas Greinacher, Johan W. M. Heemskerk, Paola E. J. van der Meijden, Thomas Thiele   +10 more
openalex   +3 more sources

Platelet-collagen interaction: is GPVI the central receptor?

Blood, 2003
AbstractAt sites of vascular injury, platelets come into contact with subendothelial collagen, which triggers their activation and the formation of a hemostatic plug. Besides glycoprotein Ib (GPIb) and αIIbβ3 integrin, which indirectly interact with collagen via von Willebrand factor (VWF), several collagen receptors have been identified on platelets ...
Bernhard Nieswandt, Steve P. Watson
openalex   +4 more sources